Individuals in different circumstances or at different stages of their lives may have different needs and preferences. People need a range of safe and effective options so they can choose what works best for them and take control of their own health. The more methods there are for PrEP, the more likely it will be that everyone at risk of HIV can find a method that suits their needs at that time. Moreover, studies are demonstrating that when more PrEP choices are available, PrEP uptake increases overall.

We contributed to the scale-up of oral PrEP and are supporting the introduction of new long-acting PrEP products. We aim to ensure users can choose the method that best suits their needs and preferences, with a particular focus on improving access for high-risk and key populations such as adolescent girls and young women, gay men and other men who have sex with men, and transgender people.

We invest in initiatives that remove barriers to accessing PrEP and integrate it into comprehensive sexual and reproductive health services, including for sexually transmitted infections, with a particular focus on adolescents.

In addition, our collaboration with the Medicines Patent Pool (MPP), other grants focused on intellectual property, and generic manufacturers is working to improve affordability and widespread availability of all PrEP choices. For example, we supported MPP to secure the generic license for long-acting cabotegravir, the first injectable form of PrEP, and are supporting generic manufacturers with product development and regulatory strategies. We also work to ensure equitable access is planned from the earliest stages for products in the pipeline.